Anne M. Traynor, MD close
Anne M. Traynor, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Anne M. Traynor, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Traynor is an Associate Professor of Medicine in the UW Carbone Cancer Center (UWCCC), specializing in the medical oncology care of patients with lung cancer. Dr. Traynor earned her medical degree at the University of North Carolina, her residency in internal medicine at the Mary Imogene Bassett Hospital in Cooperstown, NY, and her medical oncology fellowship training at the University of Iowa Hospitals and Clinics. She has been on faculty at the UWCCC since 2002. 


Medical Oncology

Lung Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Fellowship University of Iowa Hospital and Clinics, Iowa City, IA
Residency Mary Imogene Bassett Hospital and Clinics, Cooperstown, NY
Medical School University of North Carolina School of Medicine, Chapel Hill, NC

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Traynor is the Faculty Director of the UWCCC Clinical Research Central Office, working to support patients and investigators in the critical endeavor of developing improved anti-cancer medicines. She previously led the Wisconsin Oncology Network, a cancer research group that conducts clinical trials throughout the state. She also previously chaired the UWCCC Lung Cancer Research Group, as well as multiple clinical research committees in the UWCCC. She represents the UWCCC in several national oncology research organizations. 

PubMed Articles
Lin JJ Zhu VW Schoenfeld AJ Yeap BY Saxena A Ferris LA Dagogo-Jack I Farago AF Taber A Traynor A Menon S Gainor JF Lennerz JK Plodkowski AJ Digumarthy SR Ou SI Shaw AT Riely GJ Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol . 2018 Oct;13(10):1530-1538
[PubMed ID: 29935304]
Engle JA Traynor AM Campbell TC Wisinski KB LoConte N Liu G Wilding G Kolesar JM Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract . 2018 Jul;24(5):348-353
[PubMed ID: 28457192]
Chang JE Carmichael LL Kim K Peterson C Yang DT Traynor AM Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk . 2018 Jan;18(1):e61-e67
[PubMed ID: 29191715]
Wakelee HA Dahlberg SE Keller SM Tester WJ Gandara DR Graziano SL Adjei AA Leighl NB Aisner SC Rothman JM Patel JD Sborov MD McDermott SR Perez-Soler R Traynor AM Butts C Evans T Shafqat A Chapman AE Kasbari SS Horn L Ramalingam SS Schiller JH ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol . 2017 Dec;18(12):1610-1623
[PubMed ID: 29129443]
Wheler J Mutch D Lager J Castell C Liu L Jiang J Traynor AM Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. Oncologist . 2017 Apr;22(4):377-e37
[PubMed ID: 28275119]
Chiappori AA Otterson GA Dowlati A Traynor AM Horn L Owonikoko TK Ross HJ Hann CL Abu Hejleh T Nieva J Zhao X Schell M Sullivan DM A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist . 2016 Oct;21(10):1163-1164
[PubMed ID: 27694157]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer . 2016 Aug;16(4):256-61
[PubMed ID: 27133732]
Schehr JL Schultz ZD Warrick JW Guckenberger DJ Pezzi HM Sperger JM Heninger E Saeed A Leal T Mattox K Traynor AM Campbell TC Berry SM Beebe DJ Lang JM High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. PLoS One . 2016;11(7):e0159397
[PubMed ID: 27459545]
King JD Eickhoff J Traynor A Campbell TC Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review. J Pain Symptom Manage . 2016 Jun;51(6):1027-32
[PubMed ID: 26948411]
Chang JE Havighurst T Kim K Eickhoff J Traynor AM Kirby-Slimp R Volk LM Werndli J Go RS Weiss M Blank J Kahl BS Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. Br J Haematol . 2016 Apr;173(2):283-91
[PubMed ID: 26913697]
Bruce JY LoRusso PM Goncalves PH Heath EI Sadowski E Shalinsky DR Zhang Y Traynor AM Breazna A Ricart AD Tortorici M Liu G A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer Chemother Pharmacol . 2016 Mar;77(3):527-38
[PubMed ID: 26791870]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract . 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Fenske TS Shah NM Kim KM Saha S Zhang C Baim AE Farnen JP Onitilo AA Blank JH Ahuja H Wassenaar T Qamar R Mansky P Traynor AM Mattison RJ Kahl BS A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. Cancer . 2015 Oct 1;121(19):3465-71
[PubMed ID: 26079295]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol . 2015 Aug;76(2):317-23
[PubMed ID: 26068189]
Nyflot MJ Kruser TJ Traynor AM Khuntia D Yang DT Hartig GK McCulloch TM Wiederholt PA Gentry LR Hoang T Jeraj R Harari PM Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. Int J Radiat Oncol Biol Phys . 2015 Apr 1;91(5):942-51
[PubMed ID: 25659884]
Boggs DH Robins HI Langer CJ Traynor AM Berkowitz MJ Mehta MP Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer . 2014 Nov;15(6):433-40
[PubMed ID: 25069747]
Rajguru S Kristinsdottir T Eickhoff J Peterson C Meyer CM Traynor AM Kahl BS Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol . 2014 Aug;12(8):509-15
[PubMed ID: 25356575]
Cannon DM Geye HM Hartig GK Traynor AM Hoang T McCulloch TM Wiederholt PA Chappell RJ Harari PM Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck . 2014 Aug;36(8):1120-5
[PubMed ID: 23804248]
Weichert JP Clark PA Kandela IK Vaccaro AM Clarke W Longino MA Pinchuk AN Farhoud M Swanson KI Floberg JM Grudzinski J Titz B Traynor AM Chen HE Hall LT Pazoles CJ Pickhardt PJ Kuo JS Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med . 2014 Jun 11;6(240):240ra75
[PubMed ID: 24920661]
Burkard ME Wisinski KB Njiaju UO Donohue S Hegeman R Stella A Mansky P Shah V Goggins T Qamar R Dietrich L Kim K Traynor AM Tevaarwerk AJ Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer . 2014 Jun;14(3):205-11
[PubMed ID: 24342730]